Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Positive Spondylitis Phase III Brings Lilly's Taltz Closer To Cosentyx's Label

Executive Summary

First of three Phase III studies of Taltz in ankylosing spondylitis is positive, using a high bar for primary endpoint efficacy. But Novartis' Cosentyx, already approved in this indication, is expected to dominate the market.


Related Content

Interview: Novartis Counts On AS and PsA For Cosentyx Growth
Pharma Q1 Results Preview: Lilly, Biogen, Amgen, GSK & Roche
Novartis' Cosentyx Goes Head-To-Head With Humira
Charting The Slow-Growing Psoriatic Arthritis Market
Novartis Has Blockbuster Targets For Cosentyx In New Autoimmune Indications


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts